-
公开(公告)号:US20220287934A1
公开(公告)日:2022-09-15
申请号:US17626106
申请日:2020-08-31
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor: Shota INOUE
Abstract: A topical composition comprises (A) at least one polyhydric alcohol having a molecular weight of 100 to 200, and (B) at least one non-polymerizable cationic compound. The component (B) may be a compound containing a metal to be a divalent or higher cation in an aqueous solution, a basic amino acid, alkanol amine, or alkyl amine, and the component (A) may be glucose, sorbitol, fructose, xylitol, or erythritol.
-
公开(公告)号:US20220031597A1
公开(公告)日:2022-02-03
申请号:US17279296
申请日:2019-09-25
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Yu KITAOKA , Mariko IWAI , Sho YAMASHINA
Abstract: Provided is a very stable topical composition. A topical composition is prepared that contains (A) from 1 to 40% by mass of at least one type selected from the group consisting of ascorbic acid and salts of ascorbic acid; (B) at least 20% by mass of a diol having three carbon atoms; (C) at least one type selected from the group consisting of tocopherol, salts of tocopherol, and derivatives of tocopherol; and (D) water, wherein the mass ratio of component (D) to component (A) is from 0.5 to 5.0 and the topical composition includes less than 20% by mass of glycol ether.
-
公开(公告)号:US11179420B2
公开(公告)日:2021-11-23
申请号:US16096973
申请日:2017-04-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Yoshifumi Ikeyama , Eiko Uno , Masayo Yumoto , Mihoko Yoshino , Xuan Trung Ngo , Hiroyuki Nishida , Akiko Uetani
IPC: C12N5/0775 , A61K35/28 , A61P29/00
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
-
公开(公告)号:US11155386B2
公开(公告)日:2021-10-26
申请号:US16094013
申请日:2016-04-25
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Shigehiko Kokubo
Abstract: A container includes a container body; and a cap that locks onto the container body, the container body and the cap being locked by putting the cap on the container body. The cap includes a cap body, a cover cap being held on the cap body so as to be displaceable and rotatable, and an urging portion that upwardly urges the cover cap. When a rotational force is applied to the cover cap being downwardly pressed, the cap body is displaced in conjunction with the cover cap, so that locking between the cap body and the container body is released, and in a state where the cover cap is not downwardly pressed, the cap body is not displaced in conjunction with the cover cap even when a rotational force is applied to the cover cap, so that locking between the cap body and the container body is not released.
-
公开(公告)号:US20210128353A1
公开(公告)日:2021-05-06
申请号:US16474006
申请日:2017-12-25
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor: Tsutomu Yabe , Atsuo Ishii
IPC: A61F9/007
Abstract: Provided is a surgical tool for ophthalmology that includes a nozzle portion capable of sucking a liquid, in which the nozzle portion includes an inner tube which is provided with an inner through-hole allowing the liquid to pass therethrough and an outer tube which accommodates the inner tube and is provided with an outer through-hole allowing the liquid to pass therethrough, in which the outer tube and the inner tube are disposed to be relatively movable, and in which the outer through-hole and the inner through-hole are disposed so that an overlapping region is changeable by the relative movement of the outer tube and the inner tube.
-
公开(公告)号:US20200171092A1
公开(公告)日:2020-06-04
申请号:US16620655
申请日:2018-05-08
Applicant: OSAKA UNIVERSITY , ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Yoshiki Sawa , Shigeru Miyagawa , Daisuke Kajita , Hayato Kurata , Kotoe Tamada , Hiroyuki Nishida
Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.
-
77.
公开(公告)号:US20190255116A1
公开(公告)日:2019-08-22
申请号:US16343330
申请日:2017-10-13
Applicant: OSAKA UNIVERSITY , ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Yoshiki Sawa , Shigeru Miyagawa , Daisuke Kajita , Kotoe Tamada
Abstract: The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.
-
公开(公告)号:US20180333436A1
公开(公告)日:2018-11-22
申请号:US15755859
申请日:2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor: Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/411
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
公开(公告)号:US20180272329A1
公开(公告)日:2018-09-27
申请号:US15764007
申请日:2016-10-19
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor: Tetsuo KOIKE , Masahiro TAKIMOTO , Yoshiki YAGI
Abstract: Provided is a cell treatment apparatus including an isolator that is configured to treat cells in the inner space maintained in aseptic conditions, and a pass box that is configured to carry an article for use in treatment of cells in the inside of the isolator or a reagent container with a reagent therein into the inside of the isolator. The pass box includes a clean bench chamber that includes an opening and closing door to enable the article to be carried thereinto and decontaminate the article, and a decontamination chamber that has a decontamination capability and is configured to be able to carry the article from the clean bench chamber into the inner space of the decontamination chamber and carry the article from the inner space of the decontamination chamber into the inside of the isolator.
-
公开(公告)号:US20180265832A1
公开(公告)日:2018-09-20
申请号:US15764036
申请日:2016-10-19
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor: Tetsuo Koike , Masahiro Takimoto , Yoshiki Yagi
Abstract: Provided is a cell treatment apparatus that includes: an isolator that has an inner space maintained in aseptic conditions and is configured to treat cells in the inner space; trays and that are each configured to house plural kinds of articles, which include reagent containers with articles and reagents therein for use in treatment of cells in the inner space of the isolator, while positioning them; and pass boxes that are configured to respectively carry the trays with the plural kinds of articles housed therein into the isolator.
-
-
-
-
-
-
-
-
-